Filtros de búsqueda

Lista de obras de

A Prospective, Randomized Trial Testing Different Regimens of Carbohydrate Administration to Prevent Major Reduction in Plasma Glucose Follwing a Standardized Bout of Moderate Physical Activity in Patients with Type 1 Diabetes

artículo científico publicado en 2020

A case series of verrucae vulgares mimicking hyperkeratosis in individuals with diabetic foot ulcers

artículo científico publicado en 2017

A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients

artículo científico publicado en 2016

A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite

artículo científico publicado en 2017

Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

artículo científico publicado en 2016

Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.

artículo científico publicado en 2017

Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials

scientific article published on 27 December 2018

Basal rate tests (24-hour fasts) performed in type-1 diabetic subjects with either absolute fasting or snacks containing negligible carbohydrate amounts result in similar glucose profiles: A randomized controlled prospective trial.

artículo científico publicado en 2017

Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum

artículo científico publicado en 2014

Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.

artículo científico publicado en 2004

Break point instead of ACE: acarbose, post-load glycaemic excursions, and cardiovascular events

artículo científico publicado en 2017

COVID-19 and diabetes mellitus: from pathophysiology to clinical management

artículo científico publicado en 2020

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial

scientific article published on 04 May 2020

Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.

artículo científico publicado en 2018

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

scientific article published on 11 November 2018

Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes

artículo científico publicado en 2011

Clinical Predictors of the Need for Further Treatment Escalation in Patients with Type 2 Diabetes on Basal Insulin Therapy - A Retrospective Observational Study

artículo científico publicado en 2019

Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure

artículo científico

Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical Perspective

artículo científico publicado en 2023

Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies

artículo científico publicado en 2010

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

artículo científico publicado en 2011

Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes

artículo científico publicado en 2020

Defects in α-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals

artículo científico publicado en 2017

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

artículo científico publicado en 2013

Diagnostic accuracy of an "amended" insulin-glucose ratio for the biochemical diagnosis of insulinomas

artículo científico publicado en 2012

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials

artículo científico publicado en 2019

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial

scientific article published on 01 May 2018

Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial

scientific article published on 04 December 2018

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

artículo científico publicado en 2008

Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial

scientific article published on 09 August 2019

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.

artículo científico publicado en 2018

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure

scientific article published on 01 March 2020

Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes

artículo científico publicado en 2020

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

artículo científico publicado en 2002

Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes

scientific article published on 26 December 2019

Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose

artículo científico publicado en 2013

Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus.

artículo científico publicado en 2017

Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis

scientific article published on 01 September 2020

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

artículo científico publicado en 2008

Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate differ

scientific article published on 27 January 2020

Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes

artículo científico publicado en 2013

Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects

artículo científico publicado en 2005

Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists

scientific article published on 03 November 2019

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

artículo científico publicado en 2005

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

artículo científico publicado en 2012

Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment

artículo científico publicado en 2016

For insulinomas, no place to hide.

artículo científico publicado en 2009

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study ⬇️

artículo científico publicado en 2010

GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family

artículo científico publicado en 2019

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes

artículo científico publicado en 2011

GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?

artículo científico publicado en 2016

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art

artículo científico publicado en 2020

GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?

scientific article published on 02 March 2020

Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes

artículo científico publicado en 2004

Gastric inhibitory polypeptide does not inhibit gastric emptying in humans

artículo científico publicado en 2003

Gastric inhibitory polypeptide: the neglected incretin revisited

artículo científico publicado en 2002

Genetic determinants predicting efficacy of glucose-lowering drugs?: a long way to go ...

artículo científico publicado en 2010

Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus

artículo científico publicado en 2003

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

artículo científico publicado en 2005

Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives

artículo científico publicado en 2002

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

artículo científico publicado en 1997

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

artículo científico publicado en 2014

Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans

artículo científico publicado en 2006

Health-related quality of life in people with type 2 diabetes participating in the LEADER trial

scientific article published on 25 October 2018

Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans

artículo científico publicado en 2010

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials

artículo científico publicado en 2020

Importance of apo E2 heterozygosity, insulin, and hypertriglyceridemia for very low density lipoproteins ⬇️

artículo científico publicado el 25 de julio de 1997

Importance of localization of insulinomas: a systematic analysis

scientific article published on 16 July 2019

Incretin hormones: Their role in health and disease

artículo científico publicado en 2018

Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials

scientific article published on 11 December 2019

Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials

artículo científico publicado en 2017

Incretin-based therapies: viewpoints on the way to consensus

artículo científico publicado en 2009

Incretin-based therapies: where will we be 50 years from now?

artículo científico publicado en 2015

Incretins and the development of type 2 diabetes

artículo científico publicado en 2006

Individualised incretin-based treatment for type 2 diabetes

artículo científico publicado en 2010

Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls

artículo científico publicado en 2006

Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

article

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes

artículo científico publicado en 2004

Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?

scientific article published on 26 August 2008

Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

artículo científico publicado en 2010

Islet amyloid in patients with diabetes due to exocrine pancreatic disorders, type 2 diabetes and non-diabetic patients

scientific article published on 09 April 2020

LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial

artículo científico publicado en 2014

Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use

artículo científico publicado en 2018

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria

article

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

artículo científico publicado en 2016

Liraglutide and Glycaemic Outcomes in the LEADER Trial

Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial

artículo científico publicado en 2019

Longitudinal Changes in Fasting and Glucose-Stimulated GLP-1 and GIP in Healthy Older Subjects

scientific article published on 01 December 2019

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

artículo científico publicado en 2019

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

artículo científico publicado en 2015

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

artículo científico publicado en 2015

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

artículo científico publicado en 2012

Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial).

artículo científico publicado en 2018

NO INCREASED RISK OF HEART FAILURE HOSPITALIZATION OR MAJOR CARDIOVASCULAR EVENTS OBSERVED WITH LIRAGLUTIDE IN PATIENTS WITH OR WITHOUT A HISTORY OF NEW YORK HEART ASSOCIATION CLASS II-III HEART FAILURE: RESULTS FROM THE LEADER TRIAL

artículo científico publicado en 2018

Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial

artículo científico publicado en 2018

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

artículo científico publicado en 2003

Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial

scientific article published on 13 November 2019

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

artículo científico publicado en 2016

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

artículo científico publicado en 2016

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

artículo científico publicado en 2014

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

scientific article published on 08 June 2019

Owning a Dog as a Determinant of Physical Activity and Metabolic Control in Patients With Type 1 and Type 2 Diabetes Mellitus

artículo científico publicado en 2019

Pancreatitis and incretin-based drugs: clarity or confusion?

artículo científico publicado en 2013

Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal Variability

artículo científico publicado en 2020

Pioneering oral peptide therapy for patients with type 2 diabetes

artículo científico publicado en 2019

Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment

scientific article published on 01 October 2005

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

Prediction of Individual Basal Rate Profiles From Patient Characteristics in Type 1 Diabetes on Insulin Pump Therapy

artículo científico publicado en 2020

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance

artículo científico publicado en 2007

Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.

artículo científico publicado en 2016

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

artículo científico publicado en 2011

Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards

artículo científico publicado en 2020

Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans

artículo científico publicado en 2007

Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care

scientific article published on 01 February 2020

Risk of hypoglycaemia associated with professional, recreational, and traffic-related activities in patients with type 2 diabetes: a cross-sectional study by questionnaire

artículo científico publicado en 2020

Risk of pancreatitis in patients treated with incretin-based therapies

artículo científico publicado en 2014

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

artículo científico publicado en 2004

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

artículo científico publicado en 2004

Self-monitoring of blood glucose in diabetes mellitus: arguments for an individualized approach

artículo científico publicado en 2009

Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects

artículo científico publicado en 2003

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

scientific article published on 03 September 2019

Sitagliptin plus basal insulin: simplifying in-hospital diabetes treatment?

artículo científico publicado en 2016

Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.

artículo científico publicado en 2004

Structural and compositional modifications of diabetic low‐density lipoproteins influence their receptor‐mediated uptake by hepatocytes ⬇️

artículo científico publicado el 1 de junio de 1997

The Novel Dual GIP and GLP-1 Receptor Agonist, Tirzepatide, Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists

artículo científico publicado en 2020

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

artículo científico publicado en 2007

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

artículo científico publicado en 2006

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

artículo científico publicado en 2016

The insulinotropic effect of pulsatile compared with continuous intravenous delivery of GLP-1.

artículo científico publicado en 2016

The reduction in hepatic insulin clearance after oral glucose is not mediated by gastric inhibitory polypeptide (GIP).

artículo científico publicado en 2003

Therapy of Type 2 Diabetes

artículo científico publicado en 2019

Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy

artículo científico publicado en 2017

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b

artículo científico publicado en 2009

Twenty-Four Hour Fasting (Basal Rate) Tests to Achieve Custom-Tailored, Hour-by-Hour Basal Insulin Infusion Rates in Patients With Type 1 Diabetes Using Insulin Pumps (CSII)

scientific article published on 21 October 2019

Uptake and metabolism of lipoproteins from patients with diabetes mellitus type II by glomerular epithelial cells ⬇️

artículo científico publicado el 1 de julio de 1997

Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials

artículo científico publicado en 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda